References

verezdo

Вестник репродуктивного здоровья

Bulletin of Reproductive Health

2075-65692310-421X

Endocrinology Research Centre (Moscow)

10.14341/brh2007122-32

verezdo-8509

Research Article

Статьи

Articles

Преждевременная недостаточность яичников: мнение экспертов

Prezhdevremennaya nedostatochnost' yaichnikov: mnenie ekspertov

Чеботникова

Т В

Chebotnikova

T V

Эндокринологический научный центр Росмедтехнологий

2007

15092007

№1 (2007)

2232

2007

Чеботникова Т.В.

Chebotnikova T.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.vrz-endojournals.ru/jour/article/view/8509

Преждевременная недостаточность яичников (пНя) — клинический синдром, типичным проявлением которого является эпизодическая или стабильная гипергонадотропная аменорея у женщин моложе 40 лет [1, 2]. Длительные нарушения менструального цикла (эпизоды гипергонадотропной аменореи и дефицита эстрогенов) рано или поздно завершаются стабильным прекращением функции яичников в довольно молодом возрасте.

References1

L.M. Nelson, S.N. Covington, R.W. Rebar. Fertil Steril 2005; 83: 1327—1332

De Moraes-Ruehsen M., Jones G.S. Premature ovarian failure. Fertil Steril 1967; 18: 440—461.

Bione S., Rizzolio F., Sala C. Mutation analysis of two candidate genes for premature ovarian failure, DACH2 and POF1B. Hum Reprod 2004; 19:2759—2766.

Jones G.S., de Morales-Ruehsen M. A new syndrome of amenorrhea in association with hypogonadotropism and apparently normal follicular apharatus. Am J Obstet Gynecol 1969; 104: 597.

Laml T., Schulz-Lobmeyr L.A. Obruca Premature ovarian failure: etiology and prospects. Gynecol Endocrinol 2000; 14; 292—302.

van Kasteren Y.M., Schoemaker J. Premature ovarian failure: a systematic review on therapeutic interventions to restore ovarian function and achieve pregnancy. Hum Reprod Update 1999; 5: 483—492.

Christin-Maitre S., Bouchard P. Genes and ovarian insufficiency. Ann Endocrinol (Paris) 1999; 60: 118— 122.

Hagerman R.J., Leavitt B.R., Farzin F. et al. FragileX-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation. Am J Hum Genet 2004; 74: 1051—1056.

WHO Scientific Group on Research on the Menopause, 1996.

Rymer J., Morris E.P. Menopausal symptoms. BMJ 2000; 321:1516—1519 (16 Dec).

Cramer D.W., Xu H., Harlow B.L. Family history as a predictor of early menopause. Fertil Steril 1995; 64: 740—745.

Gosden R.G., Treloar S.A., Martin N.G. Prevalence of premature ovarian failure in monozygotic and dizygotic twins. Hum Reprod 2007; 22: 610—615. Epub 2006 Oct 25.

van Kasteren Y.M. Familial idiopathic premature ovarian failure: an overrated and underestimated genetic disease? Hum Reprod 1999; 14: 2455— 2459.

Davis J.C. Female sex preponderance for idiopathic familial premature ovarian failure suggests an X chromosome defect: opinion. Hum Reprod. 2000; 15: 2418—2422.

Zinn A.R., Tonk V.S., Chen Z. Evidence for a Turner syndrome locus or loci at Xp11.2-p22.1. Am J Hum Genet 1998; 63: 1757—1766.

Davison R.M., Quilter C.R., Webb J. A familial case of X chromosome deletion ascertained by cytogenetic screening of women with premature ovarian failure. Hum Reprod 1998; 13: 3039—3041.

Powell C.M., Taggart R.T., Drumheller T.C. Molecular and cytogenetic studies of an X; autosome translocation in a patient with premature ovarian failure and a review of the literature. Am J Med Genet 1994; 52: 19—26.

Rebar R.W., Erickson G.F., Yen S.S.C. Idiopathic premature ovarian failure: clinical and endocrine characteristics. Fertil Steril 1982; 37: 35—41.

Марченко л.А., Залетаев Д.В. генетическая гетерогенность преждевременного истощения яичников и наследственные факторы ранней менопаузы. пробл репрод 2007; 1: 6—12.

Marozzi A., Vegetti W., Manfredini E. et al. Association between idiopathic premature ovarian failure and fragile X premutation. Hum Reprod 2000; 15: 197—202.

Sherman S L. Premature ovarian failure in the fragile X syndrome. Am J Med Genet 2000; 97: 189— 194.

Hagerman R.J., Hagerman P.J. The fragile X premutation: into the phenotypic fold. Curr Opin Genet Dev 2002; 12: 278—283.

Aittomaki K., Lucena J.L.D., Pakarinen P. et al. Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure. Cell 1995; 82: 959—968.

Aittomaki K., Herva R., Stenman U.H. et al. Clinical features of primary ovarian failure caused by a point mutation in the follicle-stimulating hormone receptor gene. JCE&M 1996; 81: 3722—3726.

Kaufman F.R., Kogut M.D., Donnell G.N. et al. Hypergonadotropic hypogonadism in female patients with galactosemia. N Engl J Med 1981; 304: 994— 998.

Crisponi L., Deiana M., Loi A. et al. The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ptosis/epicanthus inversus syndrome. Nat Genet 2001; 27: 159—166.

Bodega B., Porta C., Crosignani P.G. et al. Mutations in the coding region of the FOXL2 gene are not a major cause of idiopathic premature ovarian failure. Mol Hum Reprod 2004; 10: 555—557.

De Baere E., Dixon M.J., Small K.W. et al. Spectrum of FOXL2 gene mutations in blepharophimosis-ptosisepicanthus inversus (BPES) families demonstrates a genotype—phenotype correlation. Hum Mol Genet 2001; 10: 1591—1600.

Fogli A., Rodriguez D., Eymard-Pierre E. et al. Ovarian failure related to eukaryotic initiation factor 2B mutations. Am J Hum Genet 2003; 72: 1544— 1550.

Di Pasquale E., Beck-Peccoz P., Persani L. Hypergonadotropic ovarian failure associated with an inherited mutation of human bone morphogenetic protein-15 (BMP15) gene. Am J Hum Genet 2004; 75: 106—111.

Ahonen P., Myllarniemi S., Sipila I. et al. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med 1990; 322: 1829— 1836.

Nagamine K., Peterson P., Scott H.S. et al. Positional cloning of the APECED gene. Nat Genet 1997; 17: 393—398.

The Finnish—German APECED Consortium. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy. Nat Genet 1997; 17: 399—403.

Hoek A., Schoemaker J., Drexhage H.A. Premature ovarian failure and ovarian autoimmunity. Endocrinol Rev 1997; 18: 107—134.

Bakalov V.K., Vanderhoof V.H., Bondy C.A. et al. Adrenal antibodies detect asymptomatic auto-immune adrenal insufficiency young women with spontaneous premature ovarian failure. Hum Reprod 2002; 17: 2096—2100.

Irvine W.J., Chan M.M.W., Scarth L. et al. Immunological aspects of premature ovarian failure associated with idiopathic Addison’s disease. Lancet 1968; 2: 883—890.

Chen S., Sawicka J., Betterle C. et al. Autoantibodies to steroidogenic enzymes in autoimmune polyglandular syndrome, Addison’s disease, and premature ovarian failure. JCE&M 1996; 81: 1871—1876.

Betterle C., Rossi A., Dalla Pria S. et al. Premature ovarian failure: autoimmunity and natural history. Clin Endocrinol 1993; 39: 35—43.

Falorni A., Laureti S., Candeloro P. et al. Steroidcell autoantibodies are preferentially expressed in women with premature ovarian failure who have adrenal autoimmunity. Fertil Steril 2002; 78: 270— 279.

Turkington R.W., Lebovitz H.E. Extra-adrenal endocrine deficiencies in Addison’s disease. Am J Med 1967; 43: 499—507.

Wheatcroft N.J., Salt C., Milford-Ward A. et al. Identification of ovarian antibodies by immunofluorescence, enzymelinked immunosorbent assay or immunoblotting in premature ovarian failure. Hum Reprod 1997; 12: 2617—2622.

Novosad J.A., Kalantaridou S.N., Tong Z.B. et al. Ovarian antibodies as detected by indirect immunofluorescence are unreliable in the diagnosis of autoimmune premature ovarian failure: a controlled evaluation. BMC Womens Health 2003; 3: 2.

Betterle C., Volpato M., Rees S.B. et al. Adrenal cortex and steroid 21-hydroxylase autoantibodies in adult patients with organ-specific autoimmune diseases: markers of low progression to clinical Addison’s disease. JCE&M 1997; 82: 932—938.

Betterle C., Volpato M., Pedini B. et al. Adrenalcortex autoantibodies and steroid-producing cells autoantibodies in patients with Addison’s disease: comparison of immunofluorescence and immunoprecipitation assays. JCE&M 1999; 84: 618—622.

Ambrosi B., Barbetta L., Morricone L. Diagnosis and management of Addison’s disease during pregnancy. J Endocrinol Invest 2003; 26: 698—702.

Stenchever M.A., Droegemueller W., Herbst A.L. et al. Primary secondary amenorrhea. In: Stenchever MA, Droegemueller W., Herbst A.L., Mishell D.R.J., eds. Comprehensive gynecology. St. Louis: Mosby, 2001: 1099—1123.

Alzubaidi N.H., Chapin H.L., Vanderhoof V.H. et al. Meeting the needs of young women with secondary amenorrhea and spontaneous premature ovarian failure. Obstet Gynecol 2002; 99: 720.

Rebar R.W., Connolly H.V. Clinical features of young women with hypergonadotropic amenorrhea. Fertil Steril 1990; 53 :804—810.

Nelson L.M., Kimzey L.M., White B.J. Gonadotropin suppression for the treatment of karyotypically normal spontaneous premature ovarian failure: a controlled trial. Fertil Steril 1992; 57: 50.

Anasti J.N. Premature ovarian failure: an update. Fertil Steril 1998; 70: 1—15.

Nelson L.M., Anasti J.N., Kimzey L.M. et al. Development of luteinized Graafian follicles in patients with karyotypically normal spontaneous premature ovarian failure. JCE&M 1994; 79: 1470 —1475.

Goldenberg R.L., Grodin R.L., Rodbard D. Gonadotropins women with amenorrhea. Am J Obstet Gynecol 1973; 116: 1003—1009.

Conway G.S., Kaltsas G., Patel A. Characterization of idiopathic premature ovarian failure. Fertil Steril 1996; 65: 337—341.

Taylor A.E., Adams J.M., Mulder J.E. A randomized, controlled trial of estradiol replacement therapy women with hypergonadotropic amenorrhea. JCE&M 1996; 81: 3615—3621.

Liao K.L., Wood N., Conway G.S. Premature menopause and psychological well-being. J Psychosom Obstet Gynaecol 2000; 21: 167—174.

Ohta H., Sugimoto I., Masuda A. et al. Decreased bone mineral density associated with early menopause progresses for at least ten years: crosssectional comparisons between early and normal menopausal women. Bone 1996; 18: 227—231.

Anasti J.N., Kalantaridou S.N., Kimzey L.M. et al. Bone loss in young women with karyotypically normal spontaneous premature ovarian failure. Obstet Gynecol 1998; 91: 12—15.

Jacobsen B.K., Knutsen S.F., Fraser G.E. Age at natural menopause and total mortality and mortality from ischemic heart disease: the Adventist Health Study. J Clin Epidemiol 1999; 52: 303—307.

de Kleijn M.J., van der Schouw Y.T., Verbeek A.L. et al. Endogenous estrogen exposure and cardiovascular mortality risk in postmenopausal women. Am J Epidemiol 2002; 155: 339—345.

Mishell D.R. Jr, Nakamura R.M., Crosignani P.G. et al. Serum gonadotropin and steroid patterns during the normal menstrual cycle. Am J Obstet Gynecol 1971; 111: 60—65.

Chetkowski R.J., Meldrum D.R., Steingold K.A. et al. Biologic effects of transdermal estradiol. N Engl J Med 1986; 314: 1615—1620.

Gibbons W.E., Moyer D.L., Lobo R.A. et al. Biochemical and histologic effects of sequential estrogen/progestin therapy on the endometrium of postmenopausal women. Am J Obstet Gynecol 1986; 154: 456—461.

Hertz R. Comments. In: Villee C.A., ed. Control of ovulation. New York: Pergamon Press, 1961: 221.

Bjarnason K., Cerin A., Lindgren R. et al. Adverse endometrial effects during long cycle hormone replacement therapy. Scandinavian Long Cycle Study Group. Maturitas 1999; 32: 161—170.

LaBarbera A.R., Miller M.M., Ober C. et al. Autoimmune etiology in premature ovarian failure. Am J Reprod Immunol 1988; 16: 115—122.

Kim T.J., Anasti J.N., Flack M.R. et al. Routine endocrine screening for patients with karyotypically normal spontaneous premature ovarian failure. Obstet Gynecol 1997; 89: 777—779.

Hartmann B.W., Kirchengast S., Albrecht A. et al. Androgen serum levels in women with premature ovarian failure compared to fertile and menopausal controls. Gynecol Obstet Invest 1997; 44: 127— 131.

Elias A.N, Pandian M.R., Rojas F.J. Serum levels of androstenedione, testosterone and dehydroepiandrosterone sulfate in patients with premature ovarian failure to age-matched menstruating controls. Gynecol Obstet Invest 1997; 43: 47—48.

Doldi N., Belvisi L., Bassan M. et al. Premature ovarian failure: steroid synthesis and autoimmunity. Gynecol Endocrinol 1998; 12: 23—28.

Smith J.A., Vitale S., Reed G.F. et al. Dry eye signs and symptoms in women with premature ovarian failure. Arch Ophthalmol 2004; 122: 151—156.

Jensen A.A., Higginbotham E.J., Guzinski G.M. et al. A survey of ocular complaints in postmenopausal women. J Assoc Acad Minor Phys 2000; 11: 44—49.

Schaumberg D.A., Buring J.E., Sullivan D.A. et al. Hormone replacement therapy and dry eye syndrome. JAMA 2001; 286: 2114—2119.

van Kasteren Y.M., Schoemaker J. Premature ovarian failure: a systematic review on therapeutic interventions to restore ovarian function and achieve pregnancy. Hum Reprod Update 1999; 5: 483— 492.

The authors declare that there are no conflicts of interest present.